Literature DB >> 16188498

Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study.

Marco Metra1, Claudia Zani, Loredana Covolo, Savina Nodari, Natalia Pezzali, Umberto Gelatti, Francesco Donato, Giuseppe Nardi, Livio Dei Cas.   

Abstract

BACKGROUND: Adrenergic activation has a central role in the development of HF. The function of the beta1- and the alpha2C-adrenergic receptors is influenced by gene polymorphisms: the beta1Arg389 variant is associated with increased beta1-receptor sensitivity and the alpha2C-receptor Del322-325 variant is associated with decreased alpha2C receptor function and increased norepinephrine release. We hypothesised that these polymorphisms could influence the prevalence of heart failure.
METHODS: The role of the beta1- and alpha2C-adrenergic receptor gene polymorphisms as risk factors for heart failure (HF) was assessed in an Italian white Caucasian population using a case-control study design. Genomic DNA was analysed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RLFP).
RESULTS: We compared 260 Caucasian patients with HF and 230 normal subjects. The beta1Arg389 allele was frequent both in the patients with HF (69%) and in the normal subjects (73%). The alpha2CDel322-325 variant was rare in both groups (9% and 8%, respectively). Patients homozygotes for either the beta1Arg389 or the alpha(2C)Del322-325 alleles had no increased risk of HF (odds ratio [OR], 0.8; 95%CI: 0.5-1.2 and OR, 0.8; 95% CI: 0.4-1.8, respectively). Patients homozygotes for both the beta1Arg389 and the alpha(2C)Del322-325 alleles had no increased risk of HF as well (OR: 0.6; 95% CI: 0.2-2.1).
CONCLUSIONS: Beta1-ARs and alpha2C-ARs polymorphisms are not associated with an increased risk of HF in an Italian white Caucasian population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16188498     DOI: 10.1016/j.ejheart.2005.07.009

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  8 in total

1.  RAAS and adrenergic genes in heart failure: Function, predisposition and survival implications.

Authors:  Alberto J Alves; Nir Eynon; José Oliveira; Ehud Goldhammer
Journal:  World J Cardiol       Date:  2010-07-26

2.  A meta-analysis of β1-adrenergic receptor gene polymorphisms in idiopathic dilated cardiomyopathy.

Authors:  Bo Jin; Qu-Zhen Ge-Shang; Yong Li; Wei Shen; Hai-Ming Shi; Huan-Chun Ni
Journal:  Mol Biol Rep       Date:  2011-05-08       Impact factor: 2.316

Review 3.  Race, common genetic variation, and therapeutic response disparities in heart failure.

Authors:  Mathew R Taylor; Albert Y Sun; Gordon Davis; Mona Fiuzat; Stephen B Liggett; Michael R Bristow
Journal:  JACC Heart Fail       Date:  2014-10-22       Impact factor: 12.035

Review 4.  Genetic prediction of heart failure incidence, prognosis and beta-blocker response.

Authors:  Fabiana Filigheddu
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

Review 5.  Chronic heart failure: beta-blockers and pharmacogenetics.

Authors:  Junichi Azuma; Shinpei Nonen
Journal:  Eur J Clin Pharmacol       Date:  2008-10-07       Impact factor: 2.953

6.  Adrenergic receptor genotype influences heart failure severity and β-blocker response in children with dilated cardiomyopathy.

Authors:  Sushma Reddy; Alan Fung; Cedric Manlhiot; Elif Seda Selamet Tierney; Wendy K Chung; Elizabeth Blume; Beth D Kaufman; Elizabeth Goldmuntz; Steven Colan; Seema Mital
Journal:  Pediatr Res       Date:  2014-11-19       Impact factor: 3.756

7.  Beta1- and alpha2c-adrenoreceptor variants as predictors of clinical aspects of dilated cardiomyopathy in people of African ancestry.

Authors:  A J Woodiwiss; D Badenhorst; K Sliwa; R Brooksbank; R Essop; P Sareli; G R Norton
Journal:  Cardiovasc J Afr       Date:  2008 Jul-Aug       Impact factor: 1.167

8.  The alpha 2C Del322-325 adrenergic receptor polymorphism is not associated with heart failure due to idiopathic dilated cardiomyopathy in black Africans.

Authors:  J Du Preez; L O Matolweni; J Greenberg; P Mntla; A A Adeyemo; B M Mayosi
Journal:  Cardiovasc J Afr       Date:  2008 Jan-Feb       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.